Natural killer group 2, member D–Natural killer group 2, member D ligand pathway (NKG2D–NKG2DL pathway)

The Natural killer group 2, member D–Natural killer group 2, member D ligand pathway (NKG2D–NKG2DL pathway) is a crucial component of the immune system’s ability to recognize and eliminate stressed, infected, or transformed (e.g., cancerous) cells. NKG2D is a type II transmembrane, activating receptor expressed primarily on natural killer (NK) cells, CD8^+^ T cells, invariant natural killer T (iNKT) cells, and γδ T cells. Its ligands (NKG2DLs) include MHC class I–related chain molecules (MICA, MICB) and UL16-binding proteins (ULBP1–6), which are typically absent or expressed at low levels in healthy cells but are induced in response to cellular stress, infection, DNA damage, or oncogenic transformation. Upon ligand binding, NKG2D triggers the release of cytolytic granules and production of cytokines, leading to destruction of the target cell. This pathway plays fundamental roles in tumor immunosurveillance, anti-viral defense, and clearance of senescent or diseased cells, but can also contribute to autoimmunity and chronic inflammation if dysregulated. Therapeutic strategies aim to enhance NKG2D–ligand interactions for cancer immunotherapy or to inhibit unwanted activation driving tissue damage in autoimmune diseases.

Other names

NKG2D/NKG2DL axisNKG2D receptor–NKG2D ligand systemNKG2D pathwayNKG2D–ligand axis

Immune activation (drugs/cell therapies enhance recognition of stressed/infected/cancer cells via NKG2D engagement); Direct cytotoxicity mediated by NK and CD8^+^ T cells after NKG2D ligation; Immunomodulation by blocking or stimulating NKG2D–ligand interaction